MUMBAI (Reuters) - Shares in Ranbaxy Laboratories Ltd fell over 5 percent in early trade after the drugmaker posted losses for a second straight quarter on Tuesday, hurt by foreign exchange charges and a one-time write-off related to one of its plants under an import ban by the U.S. health regulator. The stock recovered later.
Net loss in July-September was 4.5 billion rupees compared with a profit of 7.5 billion rupees a year earlier, it said on Tuesday.
At 10:19 a.m., Ranbaxy was trading 1.26 percent lower at 380.60 rupees.
(Reporting by Abhishek Vishnoi; Editing by Subhranshu Sahu)
View the original article here
No comments:
Post a Comment